Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100972 | 0.83 | NPC1 (0.46) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL5286958 | 0.83 | RAB9A (0.44) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL22593395 | 0.80 | NPC1 (0.45) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL5250663 | 0.79 | NPC1 (0.42) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL8186357 | 0.77 | CTSK (0.45) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL4446826 | 0.77 | CES2 (0.49) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL3962690 | 0.77 | CES2 (0.49) | NPC1RAB9ACES2CES1KEAP1 | |
| Bicarbonate SCHEMBL5247907 | 0.77 | CES2 (0.49) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL18884424 | 0.77 | AOC3 (0.50) | NPC1RAB9ACES2CES1KEAP1 | |
| SCHEMBL6607482 | 0.77 | SLC6A3 (0.51) | NPC1RAB9ACES2CES1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166567-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166567-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | CHEK1, CHEK2, TTK | NPC1 3762/4885RAB9A 2523/4885CES2 4707/4885 |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | CHEK1, CHEK2, TTK | NPC1 3762/4885RAB9A 2523/4885CES2 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.